<DOC>
	<DOCNO>NCT00084669</DOCNO>
	<brief_summary>RATIONALE : Venlafaxine may effective relieve hot flash cause hormone therapy . Giving venlafaxine zolpidem ( sleep pill ) may improve sleep quality life woman receive hormone therapy treatment prevention breast cancer . PURPOSE : This randomized clinical trial study give venlafaxine together zolpidem see well work compare venlafaxine alone relieve hot flash associate sleep disorder woman receive hormone therapy treat prevent breast cancer .</brief_summary>
	<brief_title>Venlafaxine With Without Zolpidem Treating Hot Flashes Associated Sleep Disorders Women With Breast Cancer OR High Risk Developing Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare effect venlafaxine another serotonin-reuptake inhibitor v without zolpidem , term sleep continuity , woman breast cancer high risk develop breast cancer experience hot flush associate sleep disorder . - Compare quality life patient treat regimen . OUTLINE : This randomize , double-blind , placebo-controlled study . Patients stratify concurrent use serotonin-reuptake inhibitor ( SRI ) . - Stratum 1 ( concurrent SRI ) : Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral venlafaxine daily oral zolpidem daily 5 weeks* . - Arm II : Patients receive oral venlafaxine daily oral placebo daily 5 weeks* . - Stratum 2 ( concurrently SRI ) : Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral zolpidem daily 5 weeks* . - Arm II : Patients receive oral placebo daily 5 weeks* . NOTE : *After 5 week study treatment , patient stratum 1 may taper continue venlafaxine 2 week ( total duration venlafaxine use 7 week ) ; patient arm I strata may taper continue zolpidem 1 week ( total duration zolpidem use 6 week ) ; continuation taper drug arm occurs open-label fashion study . In stratum , treatment continue absence unacceptable toxicity . In stratum , hot flush , sleep continuity , sleep quality , quality life assess baseline week 1 , 3 , 6 . PROJECTED ACCRUAL : A total 119 patient accrue study within 20 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<mesh_term>Zolpidem</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : At increase risk develop breast cancer , meet 1 follow criterion : Diagnosis 1 following : Ductal carcinoma situ Invasive breast cancer Lobular carcinoma situ Atypical ductal lobular hyperplasia Lobular carcinoma Candidate breast cancer risk reduction follow : Predisposing mutation breast cancer susceptibility gene Prior chest radiotherapy Hodgkin 's disease Gail model score &gt; 1.67 % 5 year Experiencing daytime nocturnal hot flush least 14 time per week within past 2 week Experiencing sleep disturbance , characterize presence follow ≥ 1 month : ≥ 3 awakening per night occur ≥ 3 night per week Insomnia impede daytime function Hot flush primary cause insomnia ( determined baseline visit ) Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 18 65 Sex Female Menopausal status Not specify Performance status ECOG 01 Life expectancy At least 6 month Hematopoietic Not specify Hepatic AST ALT ≤ 2.5 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 time ULN Renal Creatinine ≤ 1.5 time ULN Cardiovascular No clinically significant cardiac disease No uncontrolled hypertension within past 3 month , define follow : Diastolic blood pressure &gt; 95 mm Hg &gt; 1 occasion Systolic blood pressure &gt; 160 mm Hg &gt; 1 occasion Pulmonary No clinically significant respiratory disease Psychiatric Beck depression inventory score ≤ 15 No active panic depressive disorder within past month No lifetime history bipolar psychotic disorder No active substanceuse disorder , include alcohol benzodiazepine , within past year No suicidal homicidal ideation No hypomania mania Other No prior adverse reaction venlafaxine zolpidem None follow sleep disorder within past 6 month : Sleep apnea Narcolepsy Periodic limb movement disturbance No abuse misuse study medication No daytime sedation interfere ability function Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception 1 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy More 3 month since prior chemotherapy No concurrent chemotherapy Endocrine therapy More 1 month since prior regular use ( &gt; 25 % time ) oral , transdermal , injection preparation androgen , estrogen , progestins Vaginal suppository cream allow No concurrent regular use oral , transdermal , injection preparation androgen , estrogen , progestin Radiotherapy See Disease Characteristics More 3 month since prior radiotherapy No concurrent radiotherapy Surgery See Disease Characteristics Other More 1 month since prior regular use ( &gt; 25 % time ) following : Hypnotic agent ( e.g. , benzodiazepine , zolpidem , zaleplon , trazodone , diphenhydramine ) Clonidine More 1 month since prior antidepressant medication know influence mood &gt; 25 % time ( serotoninreuptake inhibitor [ SRI ] stratum ) Concurrent SRI require provide initiated ≥ 1 month ago minimum dose , include follow ( concurrent SRI stratum ) : Fluoxetine Paroxetine Paroxetine CR Sertraline Citalopram Scitalopram Venlafaxine Fluvoxamine No concurrent warfarin No concurrent hypnotic agent , clonidine , antidepressant , medication know influence sleep , mood</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>hot flash</keyword>
	<keyword>sleep disorder</keyword>
	<keyword>ductal breast carcinoma situ</keyword>
	<keyword>breast cancer situ</keyword>
	<keyword>lobular breast carcinoma situ</keyword>
	<keyword>lobular breast carcinoma</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
</DOC>